Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

SILICOFCM · In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy

H2020Status: CLOSED1 June 201828 February 2022EU funding €5,507,441Call H2020-SC1-2016-2017

According to the 2014 European Society of Cardiology Guidelines, cardiomyopathies are defined as structural and functional abnormalities of the ventricular myocardium that are unexplained by flow limiting coronary artery disease or abnormal loading conditions. There are four major classifications of cardiomyopathy: hypertrophic (HCM), dilated (DCM), restrictive (RCM), and arrhythmogenic right ventricular (ARVC). Familial cardiomyopathies (FCM) are most commonly diagnosed, or progress of the disease is monitored, through in vivo imaging, with either echocardiography or, increasingly, cardiac magnetic resonance imaging (MRI). The treatment of symptoms of FCM by established therapies could only in part improve the outcome, but novel therapies need to be developed to affect the disease process and time course more fundamentally. SILICOFCM project will develop in silico computational cloud platform which will integrate from stopped-flow molecular kinetic assays to magnetic resonance imaging of the whole heart, bioinformatics and image processing tools with state of the art computer models with the aim to reduce animal and clinical studies for a new drug development and optimized clinical therapy of FCM.The developed system will be distributed on the cloud platforms in order to achieve efficient data storage and high-performance computing, that can offer end users results in reasonably short time. Academic technical partners IIT, UOI, UL and BSC will be responsible for developing and integration of in silico cloud computational platform with multi-scale cardiac muscle modelling which include experiments on protein mutation in vitro from UNIKENT, UNIFI and UW. Bioinformatics tools will be integrated by US company SBG. Clinical partners UNEW, ICVDV, UPMC and UHREG will do retrospective and prospective studies. SME partner R-Tech will be in charge of regulatory issues and reports and BIOIRC will do the exploitation of the project.

Consortium · 19 organisations

coordinator

ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO

RS · €721,750

thirdParty

SEVEN BRIDGES GENOMICS D.O.O. BEOGRAD

RS

thirdParty

SEVEN BRIDGES GENOMICS BIYOTEKNOLOJI ANONIM SIRKETI

TR

participant

UNIVERSITY OF WASHINGTON

US · €450,201

participant

ILLINOIS INSTITUTE OF TECHNOLOGY

US · €417,750

participant

SEVEN BRIDGES GENOMICS INC

US · €339,375

participant

KLINIKUM DER UNIVERSITAET REGENSBURG

DE · €374,625

participant

UNIVERSITA DEGLI STUDI DI FIRENZE

IT · €475,100

participant

FACULTY OF MEDICINE, UNIVERSITY OF BELGRADE

RS · €180,250

participant

UNIVERSITY OF NEWCASTLE UPON TYNE

UK · €604,090

participant

INSTITUT ZA KARDIOVASKULARNE BOLESTI VOJVODINE

RS · €445,750

thirdParty

UNIVERSITY OF NOVI SAD, FACULTY OF MEDICINE NOVI SAD

RS

participant

UNIVERSITY OF KENT

UK · €413,550

thirdParty

SEVEN BRIDGES GENOMICS UK LTD

UK

participant

PANEPISTIMIO IOANNINON

EL · €276,375

participant

STEINBEIS EU-VRI GMBH

DE · €278,750

participant

UNIVERZA V LJUBLJANI

SI · €187,500

participant

BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION

ES · €342,375

participant

SORBONNE UNIVERSITE

FR

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.